Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate UpdatesGlobeNewsWire • 11/04/25
Biotech is back. Here's why these rallying stocks belong in your portfolio now.Market Watch • 11/03/25
Madrigal (MDGL) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 10/28/25
Madrigal to Present New Data from the Company's MASH Program at AASLD's The Liver Meeting 2025GlobeNewsWire • 10/28/25
Madrigal Pharmaceuticals: Rezdiffra Commercialization Bodes Well For Continued GrowthSeeking Alpha • 10/26/25
Madrigal Pharmaceuticals to Release Third-Quarter 2025 Financial Results and Host Webcast on November 4, 2025GlobeNewsWire • 10/22/25
Madrigal Pharmaceuticals, Inc. (MDGL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)Seeking Alpha • 09/08/25
Madrigal Pharmaceuticals to Participate in Morgan Stanley 23rd Annual Global Healthcare ConferenceGlobeNewsWire • 09/03/25
Madrigal Receives European Commission Approval for Rezdiffra™ (resmetirom) for the Treatment of MASH with Moderate to Advanced Liver FibrosisGlobeNewsWire • 08/19/25
Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth ConferenceGlobeNewsWire • 08/11/25
Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and Provides Corporate UpdatesGlobeNewsWire • 08/05/25
Madrigal Pharmaceuticals: Rezdiffra Expansion Avenues Shift Focus To Long TermSeeking Alpha • 07/31/25
Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group LimitedGlobeNewsWire • 07/30/25
Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August 5, 2025GlobeNewsWire • 07/25/25
Madrigal Pharmaceuticals Secures $500 Million in Senior Secured Credit from Blue Owl Managed Funds to Further Extend Leadership Position in MASHGlobeNewsWire • 07/22/25
MDGL Stock Soars 11% on New Patent Protecting Rezdiffra Dosing RightsZacks Investment Research • 07/17/25
Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra™ (Resmetirom)GlobeNewsWire • 07/16/25